Phase III Trial Investigates Novel Combination Therapy for Advanced Kidney Cancer

The LITESPARK-033 Phase III clinical trial is currently evaluating a new combination of belzutifan and zanzalintinib. This study targets patients with clear cell renal cell carcinoma who have progressed after prior treatment with pembrolizumab. The trial aims to address an unmet need for additional treatment options in this specific patient population, comparing the new combination against cabozantinib.